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We assessed the association of sex hormone levels with breast cancer risk in a case–control study nested within the cohort of 7054
New York University (NYU) Women’s Health Study participants who were postmenopausal at entry. The study includes 297 cases
diagnosed between 6 months and 12.7 years after enrollment and 563 controls. Multivariate odds ratios (ORs) (95% confidence
interval (CI)) for breast cancer for the highest quintile of each hormone and sex-hormone binding globulin (SHBG) relative to the
lowest were as follows: 2.49 (1.47–4.21), Ptrend¼0.003 for oestradiol; 3.24 (1.87–5.58), Ptrendo0.001 for oestrone; 2.37 (1.39–
4.04), Ptrend¼0.002 for testosterone; 2.07 (1.28–3.33), Ptrendo0.001 for androstenedione; 1.74 (1.05–2.89), Ptrendo0.001 for
dehydroepiandrosterone sulphate (DHEAS); and 0.51 (0.31–0.82), Ptrendo0.001 for SHBG. Analyses limited to the 191 cases who
had donated blood five to 12.7 years prior to diagnosis showed results in the same direction as overall analyses, although the tests for
trend did not reach statistical significance for DHEAS and SHBG. The rates of change per year in hormone and SHBG levels,
calculated for 95 cases and their matched controls who had given a second blood donation within 5 years of diagnosis, were of small
magnitude and overall not different in cases and controls. The association of androgens with risk did not persist after adjustment for
oestrone (1.08, 95% CI¼0.92–1.26 for testosterone; 1.15, 95% CI¼0.95–1.39 for androstenedione and 1.06, 95% CI¼0.90–1.26
for DHEAS), the oestrogen most strongly associated with risk in our study. Our results support the hypothesis that the associations of
circulating oestrogens with breast cancer risk are more likely due to an effect of circulating hormones on the development of cancer
than to elevations induced by the tumour. They also suggest that the contribution of androgens to risk is largely through their role as
substrates for oestrogen production.
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Nine prospective studies have now reported on the association
between endogenous sex hormone levels in postmenopausal
women and subsequent breast cancer risk (Moore et al, 1986;
Wysowski et al, 1987; Barrett-Connor et al, 1990; Gordon
et al, 1990; Garland et al, 1992; Helzlsouer et al, 1994; Toniolo
et al, 1995; Berrino et al, 1996; Dorgan et al, 1996; Thomas
et al, 1997; Zeleniuch-Jacquotte et al, 1997; Hankinson et al, 1998;
Cauley et al, 1999; Kabuto et al, 2000). The Endogenous Hormones
and Breast Cancer Collaborative Group (TEHBCCG) conducted a
pooled analysis of the original data of these studies and concluded
that both oestrogen and androgen hormones were strongly
associated with risk (TEHBCCG, 2002). Remaining questions
include how long prior to diagnosis the associations between
hormone levels and breast cancer are observed and whether
androgens play a part independent of their role as substrates
for oestrogen production. The New York University (NYU)
Women’s Health Study was one of the first prospective
studies to report a positive association between oestrogens
and androgens and breast cancer risk (Toniolo et al, 1995). We
expand here our initial results that were based on 130 cases for
oestrogen analyses and 85 cases for androgen analyses. The
present report includes 297 cases diagnosed between 6 months
and 12.7 years after enrollment in the study. This study has nearly
twice as many cases as any previously published cohort study.
Owing to the large sample size and extended follow-up, we were
able to assess the association of breast cancer risk with hormone
levels in serum samples collected five or more years prior to
diagnosis. To explore whether the presence of a growing cancer
results in an increase in circulating hormone levels, we also
examined the rate of change per year in hormone and sex-
hormone binding globulin (SHBG) levels in 95 cases and their
matched controls who contributed a second blood donation within
5 years of diagnosis.
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The NYU Women’s Health Study cohort
Between 1985 and 1991, the NYU Women’s Health Study enrolled
14275 healthy women aged 34–65 years at the Guttman Breast
Diagnostic Institute, a breast cancer screening centre in New York
City (Toniolo et al, 1991, 1995). Women who had been pregnant or
taken hormonal medications in the 6 months preceding their visit
were not eligible. Women were classified as postmenopausal if they
reported no menstrual cycles in the previous 6 months, a total
bilateral oophorectomy, or a hysterectomy without total oophor-
ectomy prior to natural menopause and their age was 52 years or
older. A total of 7054 participants (49.4%) were postmenopausal at
the time of initial blood donation. After written informed consent
was obtained, demographic, medical, anthropometric, reproduc-
tive, and dietary data were collected through self-administered
questionnaires. Nonfasting peripheral venous blood (30ml) was
drawn prior to breast examination. After centrifugation, serum
samples were divided into 1ml aliquots and immediately stored at
 801C for subsequent biochemical analyses. Up to 1991, women
who returned for annual breast cancer screening were invited to
contribute additional blood donations.
Nested case–control study of breast cancer
Breast cancer cases were identified through active follow-up of the
cohort by mailed questionnaires approximately every 2–4 years
and telephone interviews for nonrespondents, as well as record
linkage with state cancer registries in New York, New Jersey, and
with the US National Death Index. A capture–recapture analysis
estimated the ascertainment rate in our cohort to be 95% (Kato
et al, 1999). Only incident cases (i.e. diagnosed at least 6 months
after blood donation) of invasive breast cancer were included to
avoid selection bias from ‘prevalent’ cases. Medical and pathology
reports were requested to confirm the diagnoses.
For each case, two controls were selected at random from the
appropriate risk sets. The risk set for a case consisted of all women
postmenopausal at enrollment who were alive and free of cancer at
the time of diagnosis of the case and who matched the case on age
at entry (76 months), date of enrollment (73 months), and
number and dates (76 months) of subsequent blood donations, if
any. Menopausal status was confirmed by measuring follicle-
stimulating hormone (FSH) in all women for whom the lagtime
between last menstrual period and blood donation was less than 2
years and all women who were less than 60 years old at entry and
reported having had a hysterectomy without complete bilateral
oophorectomy and women with FSH levels p12.75mIUml
 1 were
excluded.
Laboratory analyses
All assays were conducted in the Hormones and Cancer Group at
the International Agency for Research on Cancer in Lyon, France.
Assays were selected based on the results of a validity study
(Rinaldi et al, 2001). Members of a matched set were always
analysed in the same batch. Oestradiol, oestrone, androstenedione,
and FSH were measured by direct double-antibody radioimmu-
noassays from DSL (Diagnostic System Laboratories, TX, USA),
testosterone and dehydroepiandrosterone sulphate (DHEAS) were
measured by direct radioimmunoassays from Immunotech
(Marseille, France) and SHBG was measured by a direct ‘sandwich’
immunoradiometric assay (Cis-Bio, Gif-sur-Yvette, France). The
mean intra- and interbatch coefficients of variation were 4.9 and
13.2% respectively for oestradiol (at a concentration of
257pmoll
 1), 6.7 and 14.4% for oestrone (at 74pmoll
 1), and
7.8 and 13.5% for androstenedione (at 1.4nmoll
 1), 8.7 and 15.8%
for testosterone (at 1.4nmoll
 1), 5.4 and 14.7% for
DHEAS (at 1.62mmoll
 1), and 5.6 and 13.5% for SHBG (at
40nmoll
 1).
Statistical methods
The distributions of known risk factors in cases and controls were
compared using the conditional logistic regression model, to take
into account the matching (Breslow and Day, 1980). To test for
differences in hormone (and SHBG) levels between case and
control subjects, we used a mixed-effects regression model taking
into account the matched design: after logarithmic transformation
to reduce departures from the normal distribution, the hormone
(or SHBG) levels were modelled as a function of a random stratum
effect (matched set) and a fixed effect for case–control status
(Cnaan et al, 1997).
To compute odds ratios (ORs), serum measurements were
categorised into quintiles, using the frequency distribution of the
cases and the controls combined. The matched set data were
analysed using conditional logistic regression (Breslow and Day,
1980). Odds ratios were computed relative to the lowest quintile.
Reported trend test P-values correspond to hormone variables
treated as ordered categorical variables. Analyses were also
performed on log-transformed continuous variables. The log2-
transformation was used because it leads to the OR associated with
a doubling in hormone level, an estimate more easily interpretable
than those obtained from other logarithmic transformations
(TEHBCCG, 2002). All P-values are two-sided.
To explore whether the presence of a growing cancer results in
an increase in circulating levels of sex hormones, we calculated the
rate of change per year in hormone and SHBG levels in the subset
of subjects for whom two blood donations were available and the
second blood donation was within 5 years of the index date. We
compared values in cases and their matched controls using a
mixed-effects regression model. These analyses were controlled for
age through the matching. We also controlled for baseline level of
hormone (or SHBG), rate of change per year in body mass index,
and time since menopause.
RESULTS
By 1 March 1998, the start date of the latest round of follow-up, 306
participants postmenopausal at enrollment were first diagnosed
with invasive adenocarcinoma of the breast 6 months or more after
entry into the study. Nine cases (3%) were excluded for the
following reasons: postmenopausal status not confirmed by FSH
analysis (two cases), lack of serum (two cases), both selected
controls developed cancer (breast or other) and their serum was
reserved for analyses in which they were the index cases (five
cases). The remaining 297 cases are included in the present
analysis. Pathology reports were obtained for 232 cases (78%), and
51 additional cases (16%) were confirmed by the Tumour
Registries. Among the 594 controls initially selected, 31 (5%) were
excluded for the following reasons: postmenopausal status not
confirmed by FSH analysis (four controls), participant had been
selected as a control for a previous case (seven controls),
participant developed breast (six controls) or another cancer (14
controls), and her serum was reserved for analyses in which she
was the index case.
Table 1 presents selected characteristics of participants. The
median age at enrollment was 60 years (range, 44–65) and the
median age at diagnosis was 66.1 years (range, 52.6–77.4).
Compared to controls, the case subjects were characterised by a
higher frequency of nulliparity (31 vs 23%, P¼0.09), a higher
frequency of history of breast biopsy (28 vs 22%, P¼0.05), a
higher median weight (68.1 vs 63.6kg, P¼0.002), and higher
median body mass index (25.7 vs 24.3kgm
 2, P¼0.007).
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levels. The median levels of all oestrogen and androgen hormones
were 5% (oestrone) to 10% (DHEAS) higher among cases than
controls. These differences were all highly statistically significant.
SHBG was 13% higher in controls than in cases (Po0.001).
Table 3 presents ORs for breast cancer by quintile of hormone
and SHBG levels. Significant trends of increasing risk with
increasing levels of all hormones were observed in matched
analyses not adjusted for additional factors (model a). As body
mass index is a determinant of circulating oestrogen levels
(Vermeulen and Verdonck, 1979; Poortman et al, 1981; Kaye
et al, 1991) and therefore on the same causal pathway as
oestrogens, we present adjusted analyses both including and
excluding this variable (plus height, as recommended by Michels
et al, 1998). Adjusting for age at menarche, parity, age at first birth,
family history of breast cancer, and history of breast biopsy, one
variable at a time (data not shown) or simultaneously (Table 3,
model b) did not materially affect the ORs. Adjusting for BMI and
height (model c) led to a reduction in ORs, which was more
pronounced for oestrogens than for androgens: The top quintile
ORs associated with oestradiol and oestrone were reduced by 17
and 18%, respectively, whereas for androgens the ORs were
reduced by 7–13%. All associations remained strongly significant.
The strongest association with breast cancer was observed for
oestrone with a 3.2-fold increase in risk for women in the highest
quintile relative to the lowest in model b (the corresponding OR
was 2.7 in model c). A strong inverse association was observed
with SHBG, with a 49% reduction in risk for women in the top
quintile, as compared to women in the lowest quintile.
Table 4 presents ORs from analyses limited to the 191 cases,
whose blood was drawn 5 or more years before diagnosis, and their
matched controls. Results were in the same direction for all the
hormones and SHBG as in the analyses including all cases,
although the ORs tended to be closer to unity and the trends were
no longer significant for DHEAS and SHBG.
A second blood sample collected within 5 years of the index date
was available for cases and controls from 95 matched sets. The mean
duration between first and second blood donations was 31 months
(s.d., 17.4 months), and the mean duration between second blood
donation and diagnosis was 28 months (s.d., 19.8 months). Table 5
reports the mean rates of change per year in hormone and SHBG
levels, separately for cases and controls. For SHBG and all hormones
except androstenedione, the mean changes per year were of very
small amplitude and the matched analysis showed no differences
between cases and controls. For androstenedione, the mean rate of
change suggested a slight increase in levels over time (i.e. with
decreasing time to diagnosis) among cases, whereas there was a
slight decrease among controls. This marginally statistically
significant difference (P¼0.09) became significant after adjusting
for baseline androstenedione level, rate of change in body mass
index and time since menopause (P¼0.01).
Table 6 presents the ORs associated with a doubling in androgen
levels with and without adjustment for oestrogen levels. In
unadjusted analyses, the ORs varied from 1.23 (testosterone and
DHEAS) to 1.33 (androstenedione) and were all highly statistically
significant. The ORs decreased slightly, but remained statistically
significant (or close to, for DHEAS) after adjustment for oestradiol.
The ORs, though, became close to one (1.06–1.15) and no longer
statistically significant after adjustment for oestrone.
DISCUSSION
In 1995, we reported a positive association between endogenous
oestrogens and breast cancer risk based on the first 130 cases
observed among the postmenopausal participants in the NYU
Table 1 Selected characteristics of study subjects, NYU Women’s Health Study, 1985–1998
Case subjects (n¼297) Control subjects (n¼563)
Age (years) at enrollment, median (10th–90th percentiles) 60 (54–64) 60 (54–64)
Age (years) at diagnosis, median (10th–90th percentiles) 66.1 (58.5–72.5)
Age (years) at menarche, median (10th–90th percentiles) 12 (11–14) 13 (11–15)
Nulliparous
* (%) 77 (30.9%) 117 (23.4%)
Age (years) at first full-term pregnancy, median (10th–90th percentiles) 25 (20 –31) 24.5 (20–30)
Age (years) at menopause, median (10th–90th percentiles) 50 (41–55) 50 (42–55)
First-degree family history of breast cancer
No 234 (78.8%) 445 (79.1%)
Yes, one affected relative X45 years old 43 (14.5%) 93 (16.5%)
Yes, one affected relative o45 years old or more than one affected relative 20 (6.7%) 25 (4.4%)
Prior breast biopsy
** (%) 83 (27.9%) 121 (21.5%)
Prior bilateral oophorectomy (%) 47 (15.8%) 78 (13.8%)
Height (cm), median (10th–90th percentiles) 163 (155–170) 162 (152–170)
Weight (kg)
***, median (10th–90th percentiles) 68.1 (54.0–84.9) 63.6 (53.6–81.7)
Body mass index (kgm
 2)
***, median (10th–90th percentiles) 25.7 (21.0–31.4) 24.3 (20.8–30.9)
*Po0.10,
**P¼0.05,
*** Po0.01.
Table 2 Median (10th and 90th percentiles) serum levels of hormones and SHBG in case and matched control subjects
Hormone (unit) Case subjects (n¼297) Control subjects (n¼563) P-value
a
Oestradiol (pmoll
 1) 88.86 (57.04–150.40) 81.78 (54.04–137.76) 0.005
Oestrone (pmoll
 1) 104.58 (68.46–175.20) 99.03 (60.20–153.51) o0.001
Testosterone (nmoll
 1) 0.87 (0.31–1.89) 0.79 (0.21–1.64) 0.002
Androstenedione (nmoll
 1) 2.70 (1.23–5.90) 2.45 (0.96–4.71) o0.001
DHEAS (mmoll
 1) 2.37 (0.92–6.39) 2.13 (0.71–5.07) 0.002
SHBG (nmoll
 1) 42.51 (22.1–76.3) 48.11 (24.0–89.6) o0.001
aP-values are from the mixed-effects regression model on log2-transformed variables, controlling for matching factors.
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years of follow-up, we confirm our initial results that increasing
circulating levels of oestradiol and oestrone are associated with
increasing risk of breast cancer. We also confirm the positive
association with testosterone levels observed previously (Zele-
niuch-Jacquotte et al, 1997). These results are in agreement with
those of most published prospective studies (TEHBCCG, 2002).
Our initial results on total oestradiol and oestrone levels
(Toniolo et al, 1995) were questioned (Kuller, 1995) because
measurements were carried out using commercial radioimmu-
noassay kits and oestradiol levels were higher than oestrone levels,
which was contrary to expectation in postmenopausal women. To
address this criticism, and prior to performing the assays reported
here, we carried out a validity study to assess various oestrogen
and androgen assays (Rinaldi et al, 2001), as recommended by
Hankinson et al (1994). This study allowed us to select direct
assays with high intrabatch reproducibility, high correlation with
indirect assays, and accurate ranking of subjects by hormone
serum concentrations. We reassayed all the sera from the previous
study using these methods. In the pooled analysis of nine
prospective studies, no differences in endogenous oestrogen- and
androgen-associated relative risks between studies that had used a
method incorporating a purification step and studies that had used
a direct, no-extraction method were found.
Oestrone, with an OR of 3.24 (95% confidence interval
(CI)¼1.87–5.58; model b) for women in the top quintile, appeared
more strongly associated with risk than oestradiol (OR¼2.49; 95%
CI¼1.47–4.21). This result is consistent with the results of the
pooled analysis of prospective studies where the OR for women in
the top quintile of oestradiol was 2.00 (95% CI¼1.47–2.71) and
for women in the top quintiles of oestradiol and oestrone were 2.19
(95% CI¼1.48–3.22), respectively (TEHBCCG, 2002). As oestra-
diol has greater potency and binds with oestrogen receptor-a with
greater affinity than oestrone (Zava et al, 1997), a stronger
association of risk with oestradiol than with oestrone is usually
expected. Measurement error is not likely to be responsible for our
Table 3 ORs (95% CI) for breast cancer by quintiles of serum sex hormone and SHBG levels among postmenopausal women in the NYU Women’s
Health Study
Quintiles
Hormone 1 2 3 4 5 P for trend
Oestradiol (pmoll
 1)
Cutpoints o62.87 62.87–77.18 77.19–92.48 92.49–116.34 4116.34
#cases/#controls 47/123 61/110 52/119 62/108 72/98
Model a
a 1.0 1.56 (0.95–2.56) 1.14 (0.69–1.89) 1.63 (0.98–2.71) 2.33 (1.40–3.88) 0.004
Model b
b 1.0 1.63 (0.98–2.69) 1.16 (0.69–1.92) 1.69 (1.00–2.84) 2.49 (1.47–4.21) 0.003
Model c
c 1.0 1.52 (0.91–2.53) 1.08 (0.64–1.80) 1.50 (0.88–2.55) 2.06 (1.18–3.60) 0.04
Oestrone (pmoll
 1)
Cutpoints o74.43 74.43–93.02 93.03–109.93 109.94–133.61 4133.61
#cases/#controls 40/132 64/108 59/113 62/110 72/99
Model a
a 1.0 2.26 (1.36–3.78) 2.12 (1.24–3.62) 2.35 (1.38–4.02) 2.97 (1.76–5.02) o0.001
Model b
b 1.0 2.44 (1.43–4.16) 2.30 (1.32–4.00) 2.46 (1.41–4.28) 3.24 (1.87–5.58) o0.001
Model c
c 1.0 2.32 (1.36–3.95) 2.08 (1.18–3.66) 2.15 (1.22–3.80) 2.67 (1.50–4.76) 0.006
Testosterone (nmoll
 1)
Cutpoints o0.42 0.42–0.66 0.67–0.94 0.95–1.39 41.39
#cases/#controls 47/125 60/112 58/114 64/108 68/103
Model a
a 1.0 1.63 (0.99–2.68) 1.51 (0.92–2.48) 1.84 (1.11–3.02) 2.15 (1.29–3.59) 0.005
Model b
b 1.0 1.69 (1.01–2.81) 1.57 (0.94–2.61) 1.93 (1.16–3.23) 2.37 (1.39–4.04) 0.002
Model c
c 1.0 1.64 (0.98–2.74) 1.50 (0.90–2.50) 1.87 (1.12–3.13) 2.05 (1.19–3.53) 0.01
Androstenedione (nmoll
 1)
Cutpoints o1.43 1.43–2.16 2.17–2.90 2.91–3.91 43.91
#cases/#controls 48/123 60/112 54/117 60/111 74/97
Model a
a 1.0 1.31 (0.82–2.10) 1.17 (0.73–1.90) 1.44 (0.89–2.33) 2.04 (1.28–3.25) 0.006
Model b
b 1.0 1.29 (0.80–2.10) 1.20 (0.74–1.97) 1.45 (0.89–2.37) 2.07 (1.28–3.33) o0.001
Model c
c 1.0 1.24 (0.77–2.03) 1.15 (0.70–1.88) 1.43 (0.87–2.34) 1.89 (1.16–3.07) o0.001
DHEAS (mmoll
 1)
Cutpoints o1.15 1.15–1.83 1.84–2.63 2.64–3.97 43.97
#cases/#controls 50/120 56/115 56/114 64/107 69/101
Model a
a 1.0 1.21 (0.76–1.94) 1.28 (0.79–2.08) 1.53 (0.95–2.47) 1.84 (1.12–3.03) 0.02
Model b
b 1.0 1.08 (0.66–1.74) 1.30 (0.80–2.13) 1.44 (0.88–2.34) 1.74 (1.05–2.89) o0.001
Model c
c 1.0 1.08 (0.66–1.75) 1.23 (0.75–2.01) 1.39 (0.85–2.27) 1.61 (0.97–2.69) o0.001
SHBG (nmoll
 1)
Cutpoints o29.70 29.70–40.39 40.40–52.31 52.32–67.85 467.85
#cases/#controls 74/98 64/108 63/109 49/123 47/125
Model a
a 1.0 0.81 (0.52–1.26) 0.73 (0.46–1.17) 0.49 (0.31–0.78) 0.50 (0.31–0.81) o0.001
Model b
b 1.0 0.77 (0.49–1.22) 0.73 (0.45–1.17) 0.46 (0.28–0.75) 0.51 (0.31–0.82) o0.001
Model c
c 1.0 0.82 (0.51–1.30) 0.78 (0.48–1.28) 0.52 (0.31–0.87) 0.58 (0.34–0.98) 0.01
aControlling for matching factors only.
bAdjusting for age at menarche (continuous), family history of breast cancer (no, one affected first-degree relative 445 years old, one
affected first-degree relative o45 years old or more than one affected first-degree relative), parity/age at first birth (nulliparous, p20 years at first full-term pregnancy, 21–25
years at first full-term pregnancy, 26–30 years at first full-term pregnancy, 430 years at first full-term pregnancy), history of total oophorectomy, and history of breast biopsy.
cAdjusting for all variables in model b, plus body mass index (ln) and height (ln).
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inversely related to the reliability of the measurements. In our
study, oestrone had a slightly lower reliability (intraclass correla-
tion coefficient (ICC)¼0.58) than oestradiol (ICC¼0.66), so that
the ORs observed with oestrone would be expected to be more
attenuated than with oestradiol. New evidence points to a role of
oestrogens in the development of breast cancer independent of
oestrogen receptor mediation, through metabolites such as 4- and
16a-hydroxyoestrogens (Yager, 2000). The stronger association of
risk with oestrone than with oestradiol could therefore result from
the higher concentrations of oestrone metabolites, themselves
resulting from the higher concentrations of oestrone than
Table 4 ORs (95% CI) for breast cancer by quintiles of serum sex hormone and SHBG levels among postmenopausal women in the NYU Women’s
Health Study with 5 or more years between blood donation and index date
Quintiles
Hormone 1 2 3 4 5 P for trend
Oestradiol (pmoll
 1)
Cutpoints o62.87 62.87–77.18 77.19–92.48 92.49–116.34 4116.34
#cases/#controls 31/75 32/69 35/77 37/77 53/70
Model a
a 1.0 1.09 (0.59–2.01) 1.04 (0.58–1.86) 1.08 (0.58–2.00) 2.03 (1.11–3.71) 0.04
Model b
b 1.0 1.08 (0.58–2.03) 1.00 (0.55–1.82) 1.13 (0.60–2.13) 2.18 (1.16–4.09) 0.001
Oestrone (pmoll
 1)
Cutpoints o74.43 74.43–93.02 93.03–109.93 109.94–133.61 4133.61
#cases/#controls 28/77 45/77 35/79 41/70 42/66
Model a
a 1.0 1.78 (0.96–3.30) 1.39 (0.71–2.73) 1.92 (0.99–3.72) 2.07 (1.08–3.96) 0.05
Model b
b 1.0 1.90 (1.00–3.60) 1.45 (0.72–2.91) 2.03 (1.02–4.06) 2.28 (1.17–4.47) 0.04
Testosterone (nmoll
 1)
Cutpoints o0.42 0.42–0.66 0.67–0.94 0.95–1.39 41.39
#cases/#controls 36/88 36/75 39/73 41/64 39/68
Model a
a 1.0 1.36 (0.75–2.45) 1.45 (0.81–2.61) 1.75 (0.97–3.16) 1.71 (0.93–3.15) 0.06
Model b
b 1.0 1.29 (0.70–2.36) 1.44 (0.79–2.63) 1.70 (0.92–3.13) 1.85 (0.99–3.48) 0.02
Androstenedione (nmoll
 1)
Cutpoints o1.43 1.43–2.16 2.17–2.90 2.91–3.91 43.91
#cases/#controls 33/83 42/70 34/72 34/73 47/68
Model a
a 1.0 1.49 (0.82–2.69) 1.19 (0.65–2.18) 1.26 (0.68–2.33) 1.81 (1.03–3.19) 0.1
Model b
b 1.0 1.47 (0.80–2.69) 1.17 (0.63–2.17) 1.27 (0.68–2.36) 1.88 (1.05–3.35) 0.004
DHEAS (mmoll
 1)
Cutpoints o1.15 1.15–1.83 1.84–2.63 2.64–3.97 43.97
#cases/#controls 33/75 39/76 39/80 37/66 41/66
Model a
a 1.0 1.20 (0.68–2.13) 1.19 (0.66–2.13) 1.34 (0.74–2.43) 1.57 (0.84–2.92) 0.18
Model b
b 1.0 1.10 (0.61–1.97) 1.15 (0.64–2.08) 1.30 (0.71–2.39) 1.48 (0.78–2.79) 0.19
SHBG (nmoll
 1)
Cutpoints o29.70 29.70–40.39 40.40–52.31 52.32–67.85 467.85
#cases/#controls 45/65 35/80 40/78 36/77 35/69
Model a
a 1.0 0.59 (0.33–1.06) 0.67 (0.38–1.19) 0.60 (0.34–1.06) 0.68 (0.38–1.22) 0.25
Model b
b 1.0 0.58 (0.32–1.06) 0.68 (0.37–1.22) 0.60 (0.34–1.08) 0.70 (0.39–1.26) 0.31
aControlling for matching factors only.
bAdjusting for age at menarche (continuous), family history of breast cancer (no, one affected first-degree relative 445years old, one
affected first-degree relative o45years old or more than one affected first-degree relative), parity/age at first birth (nulliparous, p20 years at first full-term pregnancy, 21–25
years at first full-term pregnancy, 26–30 years at first full-term pregnancy, 430 years at first full-term pregnancy), history of total oophorectomy, and history of breast biopsy.
Table 5 Mean rates of change per year in hormone and SHBG levels in 95 cases and 172 matched controls who had a second preindex date
measurement within 5 years of diagnosis
Mean rates of change
a per year
Hormone
Crude Adjusted
b
Cases Controls P-value Cases Controls P-value
Oestradiol (pmoll
 1)  0.005  0.015 0.71 0.002  0.018 0.45
Oestrone (pmoll
 1) 0.007  0.013 0.33 0.008  0.015 0.28
Testosterone (nmoll
 1) 0.045 0.048 0.97 0.069 0.030 0.50
Androstenedione (nmoll
 1) 0.080  0.017 0.09 0.104  0.034 0.01
DHEAS (mmoll
 1)  0.018  0.012 0.82  0.015  0.012 0.91
SHBG (nmoll
 1) 0.001  0.043 0.14  0.011  0.035 0.41
aRate of change¼[log2 (hormone at second visit) log2 (hormone at first visit)]/[number of years between visits].
bAdjusted for log2 baseline level, rate of change in body mass
index and time since menopause.
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yoestradiol observed in postmenopausal women. Finally, it has been
argued that a stronger association would be observed with the
fraction of oestradiol not bound to SHBG, because it is readily
available to breast cells, than with total oestradiol, as we (Toniolo
et al, 1995) and others (TEHBCCG, 2002) have previously found.
But because we did not measure the various oestrogen fractions in
this study we could not assess this possibility.
Whereas oestrogens are known to directly stimulate breast cell
proliferation, it is not clear whether the role of androgens is only as
precursors of oestrogens, or whether they have a direct role in
breast cancer development through conversion into oestrogens in
the breast itself or by direct stimulation of the growth and division
of breast cells. Multivariate analysis, which is mostly used to
control for confounding, may also be used to assess underlying
mechanisms (Szklo and Nieto, 1999): If an association of
androgens with breast cancer risk persisted after adjusting for
oestrogens, it would indicate that androgens may act through more
direct mechanisms in addition to increasing oestrogen levels. In
our study, the association of androgens with risk persisted after
adjustment for oestradiol, but not after adjustment for oestrone,
the oestrogen that was most strongly associated with risk in these
data (Table 6). These results suggest that the contribution of
androgens to breast cancer risk is largely through their role as
substrates for oestrogen production. These analyses, though, did
not take into account the error in measurement resulting from
using a single serum sample to quantify a woman’s long-term
average hormone levels. We attempted to correct our estimates for
such measurement error (Kim and Zeleniuch-Jacquotte, 1997),
using the repeated measurement data from the 317 controls who
had contributed two blood donations. The reliability correlation
coefficients estimated from these data were: 0.66 (95% CI¼0.61–
0.70) for oestradiol, 0.58 (95% CI¼0.53–0.63) for oestrone, 0.63
(95% CI¼0.58–0.67) for testosterone, 0.64 (95% CI¼0.59–0.68)
for androstenedione, and 0.92 (95% CI¼0.91–0.93) for DHEAS,
respectively. Our attempts to correct for measurement error,
though, led to uninterpretable results because of the instability in
the corrected estimates resulting from the multicollinearity among
hormone variables: among controls, the Spearman’s correlation
coefficients for testosterone, androstenedione, and DHEAS with
oestradiol were 0.47, 0.43, and 0.42, respectively, and with oestrone
were 0.57, 0.51, and 0.57 respectively.
The oestradiol-adjusted ORs associated with a doubling of
androgen levels that we observed were very similar to those
observed in the pooled analysis of prospective studies (TEHBCCG,
2002), that is, 1.27 for androstenedione (vs 1.26 in our study), 1.15
for DHEAS (vs 1.16), and 1.32 for testosterone (vs 1.17). Oestrone-
adjusted ORs were not presented in that study. Whether the
contribution of androgens to breast cancer risk is direct or
indirect, it would be of interest to identify the source of elevated
levels of androgens. The increased DHEAS serum concentrations
in women who develop breast cancer suggest increased adrenal
androgen secretion. In a prospective study including 53 post-
menopausal cases, Dorgan et al (2001) assessed the androstene-
dione:11b-hydroxyandrostenedione ratio, which is depressed
when the adrenals are the primary source of androstenedione
but elevated when the ovaries are the primary source. They
concluded that both the adrenals and the ovaries appear to
contribute to elevated androstenedione levels in postmenopausal
women. Further research on the factors that contribute to elevated
androgen levels is warranted.
The weak association of breast cancer risk with DHEAS that we
observed in our initial analysis (Zeleniuch-Jacquotte et al, 1997)
became stronger with the increased sample size. A substantial
association was also observed in several prospective studies and in
the pooled analysis of these studies. The risk for women in the
highest quintile of DHEAS was 60% higher than for women in the
lowest quintile. DHEAS can be converted into DHEA, itself
convertible to androstenedione. DHEAS can also be converted
into 5-androstenediol, which in postmenopausal women has
oestrogenic properties through binding to oestrogen receptors
(Seymour-Munn and Adams, 1983). As pointed out previously,
these results should caution against the use of DHEA as a
supplement with various ‘antiageing’ properties (Hankinson et al,
1998). DHEA oral supplementation leads to significant increases in
circulating levels of DHEAS, testosterone, androstenedione,
oestrone, and oestradiol (Genazzani et al, 2001).
Adjusting for body mass index resulted in an attenuation of the
ORs associated with oestrogen levels. These results were expected
in the light of the role of adipose tissue in producing oestrogens in
postmenopausal women. Spearman’s correlation coefficients of
body mass index with oestradiol and oestrone were 0.39 and 0.34,
respectively. Although smaller, an attenuation of the ORs
associated with androgen levels was also observed. A positive
association of obesity with increased levels of testosterone has
been reported (TEHBCCG, 2003). Obesity could therefore con-
tribute to breast cancer by increasing the amount of androgens
available for conversion to oestrogens, in addition to increasing
their rate of conversion. The weak positive correlations between
body mass index and androgen levels that we observed: 0.13, 0.17,
and 0.09 with testosterone, androstenedione, and DHEAS,
respectively, are consistent with such an effect.
To further investigate whether elevated levels of sex hormones
are involved in the induction of breast cancer and not simply a
byproduct of the tumour, we conducted an analysis limited to the
191 cases who had donated blood 5 or more years prior to
diagnosis. This analysis showed results in the same directions as
overall analyses, although the tests for trend did not reach
statistical significance for DHEAS and SHBG. Our study is the first
to assess the association of breast cancer risk with circulating
levels of sex hormones measured well before diagnosis in a fairly
large group of cases. The results suggest that the observed
associations are more likely due to an effect of circulating
hormones on the development of clinical cancer than to an
increase in circulating hormone levels induced by the tumour.
The availability of a second measurement within 5 years of the
index date for cases and controls from 95 matched sets allowed us
to examine changes in the levels of hormones and SHBG prior to
the index date. If the elevated levels of hormones observed in case
subjects were due to the presence of tumours, then these levels
would be expected to increase at a faster rate in cases (as they
approach diagnosis) than in controls. The mean rate of change of
androstenedione indicated a slight increase in serum levels in cases
but not in controls. However, for all other hormones and SHBG,
changes were of negligible amplitude and not significantly
different in cases and controls. These results suggest that the
presence of the growing tumour does not have a major effect on
circulating levels of sex hormones or SHBG.
Table 6 ORs for breast cancer associated with a doubling in androgen
and SHBG levels, with and without adjustment for oestrogen levels
Adjusted for
Unadjusted Oestradiol Oestrone
Testosterone
OR (95% CI) 1.23 (1.08–1.41) 1.17 (1.00–1.36) 1.08 (0.92–1.26)
P-value 0.001 0.04 0.31
Androstenedione
OR (95% CI) 1.33 (1.13–1.57) 1.26 (1.05–1.52) 1.15 (0.95–1.39)
P-value o0.001 0.01 0.15
DHEAS
OR (95% CI) 1.23 (1.07–1.42) 1.16 (0.99–1.36) 1.06 (0.90–1.26)
P-value 0.004 0.06 0.47
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in the present analysis all the case subjects in our previous report if
diagnosed after 6 months in the study, namely, 82 cases (28% of
the total) and their controls included in our initial report were
reassayed and included in this report. Excluding these subjects did
not materially affect the results (data not shown).
In conclusion, our results show that the associations
between oestrogen and androgen levels and breast cancer risk
are present 5 or more years prior to diagnosis and therefore more
likely represent an effect of circulating hormones than of the
tumour. This is a key finding towards establishing that sex
hormones are causally related to breast cancer. Our results
also suggest that the contribution of androgens to breast cancer
risk is largely through their role as substrates for oestrogen
production.
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